The present invention relates to an oral dosage form for the immediate release of bendroflumethiazide and controlled release of a second active agent, and a method for its preparation.

A fixed ratio low dose combination of benazepril and a thiazide diuretic is useful for treating hypertension particularly having about 4-6 mg of benazepril hydrochloride and about 5-7.5 mg of hydrochlorothiazide per dosage form. Suitable alternative thiazide derivatives are bendroflumethiazide chlorthalidone chlorothiazide hydroflumethiazide methylchlorothiazide polythiazide trichlormethiazide benzthiazide and cyclothiazide.

PURPOSE: To prepare a composition comprising bezenapril or its salt and a thiazide diuretic agent and capable of treating a lesser degree to a medium degree of hypertension in a lower dose than that when used alone. CONSTITUTION: This composition comprises bezenapril in about 4-6mg preferably about 5mg dose at a time or its pharmaceutically permissible salt and a thiazide diuretic agent in an amount of 80-120% preferably 100% based on 1/8 of the minimal antihyopertensive initial dose recommended...

PURPOSE: To prepare a composition comprising bezenapril or its salt and a thiazide diuretic agent and capable of treating a lesser degree to a medium degree of hypertension in a lower dose than that when used alone. CONSTITUTION: This composition comprises bezenapril in about 4-6mg preferably about 5mg dose at a time or its pharmaceutically permissible salt and a thiazide diuretic agent in an amount of 80-120% preferably 100% based on 1/8 of the minimal antihyopertensive initial dose recommended...

PURPOSE: To prepare a composition comprising bezenapril or its salt and a thiazide diuretic agent and capable of treating a lesser degree to a medium degree of hypertension in a lower dose than that when used alone. CONSTITUTION: This composition comprises bezenapril in about 4-6mg preferably about 5mg dose at a time or its pharmaceutically permissible salt and a thiazide diuretic agent in an amount of 80-120% preferably 100% based on 1/8 of the minimal antihyopertensive initial dose recommended...

Dipeptides and amino acids of the formula A-E-G are disclosed wherein A is e.g. hydrogen or a- RbCO or RbSO2- where Ra and Rb are e.g. alkyl cycloalkyl or aryl;whereinR' is e.g. alkyl;n is 0 1;R2 is e.g. hydrogen or alkyl;R3 is OH NH2are e.g. alkyl;R4 is e.g. hydrogen or alkylR6 is H or methyl;R7 is e.g. hydrogen or alkyl;R8 is e.g. hydrogen methyl or cycloalkyl such that when R8 is cycloalkyl R6 and R7 are hydrogen;R9 is e.g. hydroxy.The compounds have enzyme inhibitor activity e.g. renin inhib...

JS22 NOVEL BENDROFLUMETHIAZIDE FORMULATIONS New bendroflumethiazide formulations in solid form are provided which are characterized by excellent disintegration and dissolution capabilities even after long periods of storage. The new bendro flumethiazide formulations for example in the form of tablets are formed of one or more excipients and a dry granulation containing one or more fillers such as lactose and starch and a preformed partial coprecipitate of bendroflumethiazide and a wetting agent ...

New bendroflumethiazide formulations in solid form are provided which are characterized by excellent disintegration and dissolution capabilities even after long periods of storage. The new bendroflumethiazide formulations for example in the form of tablets are formed of one or more excipients and a dry granulation containing one or more fillers such as lactose and starch and a preformed partial coprecipitate of bendroflumethiazide and a wetting agent therefor such as polyvinyl pyrrolidone which ...

New bendroflumethiazide formulations in solid form are provided which are characterized by excellent disintegration and dissolution capabilities even after long periods of storage. The new bendroflumethiazide formulations for example in the form of tablets are formed of one or more excipients and a dry granulation containing one or more fillers such as lactose and starch and a preformed partial coprecipitate of bendroflumethiazide and a wetting agent therefor such as polyvinyl pyrrolidone which ...